Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics announced the grant of 58,500 restricted stock units and options to purchase 17,000 shares to six newly hired employees as a material inducement for employment. The awards were granted under the 2022 Inducement Plan with an exercise price of $31.26 per share, reflecting the company's continued hiring and growth in its commercial-stage dermatology business.